Category Archives: General

Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab being developed to treat relapsing forms of MS including clinicallyContinue reading “Multiple Sclerosis Biosimilars Landscape”